SMN-Rx, the antisense drug developed by Isis Pharmaceuticals, had already completed one study earlier this year.
Now the drug is ready to enter a follow up study which is an open-label, dose escalation study to assess the safety, tolerability and dose-range finding of multiple doses delivered intrathecally.
Columbia University Medical Center and University of Utah
School of Medicine are already recruiting male and female
candidates between the ages of 2 and 15 years with clinical
signs attributable to spinal muscular atrophy.
Details of this study can be found at the Clinical Trials website.
More information on ISIS SMN-Rx can be found here.
Now the drug is ready to enter a follow up study which is an open-label, dose escalation study to assess the safety, tolerability and dose-range finding of multiple doses delivered intrathecally.
Columbia University Medical Center and University of Utah
School of Medicine are already recruiting male and female
candidates between the ages of 2 and 15 years with clinical
signs attributable to spinal muscular atrophy.
Details of this study can be found at the Clinical Trials website.
More information on ISIS SMN-Rx can be found here.
Comments
Post a Comment